Quantumzyme Corp. (OTC: QTZM), a leader in computational enzyme engineering and green chemistry innovation, announced the publication of its research on sustainable ibuprofen synthesis in RSC Sustainability, a journal of the Royal Society of Chemistry. The peer-reviewed article, titled “In silico enzyme engineering of aldehyde dehydrogenase for eco-friendly ibuprofen synthesis” (DOI: 10.1039/D5SU00073D), validates the company's enzymatic process for ibuprofen production, which uses digital biology and advanced enzyme design to create a green, efficient, and scalable alternative to traditional chemical synthesis.
The technology validation confirms the feasibility and robustness of Quantumzyme's computationally engineered enzymes. The process significantly reduces reliance on harsh reagents, minimizes reaction steps, and improves yield, aligning with global green chemistry goals. It demonstrates potential for large-scale Active Pharmaceutical Ingredient (API) manufacturing with a reduced environmental footprint.
Naveen Kulkarni, CEO of Quantumzyme Corp., stated, “This publication is a strong validation of our vision to transform pharmaceutical manufacturing through sustainable innovation. By combining computational enzyme engineering with green chemistry principles, we are paving the way for cleaner, smarter, and future-ready solutions for the industry.” This milestone reinforces Quantumzyme's commitment to sustainable pharmaceutical technologies and strengthens its position as a leader in environmentally responsible drug manufacturing.
Quantumzyme Corp. is a biotransformation company that specializes in green chemistry, using quantum mechanics, molecular modeling, AI-driven simulations, and computational enzyme engineering to design high-performance biocatalysts that enhance efficiency, reduce waste, and minimize environmental impact. The company integrates computational modeling with wet-lab validation to deliver scalable, cost-effective biocatalysis solutions for industrial sustainability. For more information, visit the company's website at www.quantumzymecorp.com and its profile on www.otcmarkets.com/stock/QTZM.
